Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

F&P Healthcare wins patent case against ResMed in UK Court

F&P Healthcare wins patent case against ResMed in UK Court

By Rebecca Howard

Nov. 13 (BusinessDesk) - Fisher and Paykel Healthcare Corp has won a patent case against ResMed in the UK in the ongoing intellectual property dispute for its face and nasal masks across various jurisdictions.

The High Court of Justice, Chancery Division, Patents Court ruled a disputed ResMed patent was invalid, with the New Zealand manufacturer entitled to recover its legal costs with the amount yet to be determined by the court, the company said in a statement.

“While today’s ruling is just one more step on the journey, it reinforces our confidence in our position and we are satisfied with progress so far,” chief executive Lewis Gradon said.

In 2016, F&P Healthcare claimed that three of ResMed's European patents were invalid in the UK and should be revoked. ResMed counterclaimed for infringement but did eventually revoke two of the patents, leaving only one before the court.

ResMed argued that patent EP 2 708 258 B1 was infringed by two of F&P Healthcare’s masks used for obstructive sleep apnea therapy, the Eson and Simplus masks. Had the patent been valid it would have been infringed. However, "the court found that the patent was invalid in its entirety." F&P Healthcare said.

Subject to any appeal, this European patent will be revoked in the UK and "this result confirms that UK patients can continue to purchase and enjoy the benefits of our high-performance masks," the New Zealand company said.

The skirmish is the latest in a far-ranging dispute between the two firms, with legal action spanning from North America to Europe to New Zealand.

In October F&P Healthcare said that the Regional Court in Munich had ruled ResMed did not infringe its patents on a German utility model patent. A further case is before the same court regarding another patent with a ruling expected in 2018, pending proceedings filed by F&P Healthcare in the European Patent Office.

In its annual report, F&P Healthcare said it had absorbed pre-tax patent litigation costs of $20.7 million during the year to March 31 and it expects to incur litigation-related expenses at a similar run-rate during the 2018 financial year.

F&P Healthcare shares slipped 0.1 percent to $13.20 but have gained 55 percent so far this year.

(BusinessDesk)

ends

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Commerce Commission: Warns Genesis Over Business Billing Errors

The Commerce Commission has issued a warning to Genesis Energy Limited about billing errors concerning electricity line charges to business customers. Genesis reported the errors to the Commission. The Commission considers that Genesis is likely to ... More>>

QV: Tax Changes Yet To Dampen Red-Hot Housing Market

Just over a month has passed since the Government announced measures aimed at dampening the rampant growth of the property market, and yet the latest QV House Price Index data shows the market hit a new high in April. The average value increased 8.9% nationally ... More>>

Stats NZ: Consents For New Homes At All-Time High

A record 41,028 new homes have been consented in the year ended March 2021, Stats NZ said today. The previous record for the annual number of new homes consented was 40,025 in the year ended February 1974. “Within 10 years the number of new homes ... More>>

The Conversation: The Outlook For Coral Reefs Remains Grim Unless We Cut Emissions Fast — New Research

A study of 183 coral reefs worldwide quantified the impacts of ocean warming and acidification on reef growth rates. Even under the lowest emissions scenarios, the future of reefs is not bright. More>>

The Conversation: Why Now Would Be A Good Time For The Reserve Bank Of New Zealand To Publish Stress Test Results For Individual Banks

Set against the backdrop of an economy healing from 2020’s annus horribilis , this week’s Financial Stability Report (FSR) from the Reserve Bank (RBNZ) was cautiously reassuring: the country’s financial system is sound, though vulnerabilities remain. More>>

Reserve Bank: Concerned About New Zealand's Rising House Prices

New Zealand house prices have risen significantly in the past 12 months. This has raised concerns at the Reserve Bank of New Zealand – Te Putea Matua about the risk this poses to financial stability. Central banks responded swiftly to the global ... More>>